These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 18303489)

  • 1. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
    Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW
    Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in electrophysiological markers of cognitive control after administration of galantamine.
    Gascoyne LE; Mullinger KJ; Robson SE; Kumar J; O'Neill GC; Palaniyappan L; Morris PG; Liddle EB; Brookes MJ; Liddle PF
    Neuroimage Clin; 2018; 20():228-235. PubMed ID: 30090697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoprotection as an Innovative Therapeutic Strategy to Cardiogenic Shock: Exploring the Potential of Cytidine-5-Diphosphocholine to Mitigate Target Organ Damage.
    González-Pacheco H; Amezcua-Guerra LM; Franco M; Arias-Mendoza A; Ortega-Hernández JA; Massó F
    J Vasc Res; 2024; 61(4):160-165. PubMed ID: 38776883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-7 nicotinic agonist improves cognition in schizophrenia.
    Marder SR
    Evid Based Ment Health; 2016 May; 19(2):60. PubMed ID: 26872633
    [No Abstract]   [Full Text] [Related]  

  • 5. Citicoline: pharmacological and clinical review, 2022 update.
    Secades JJ; Gareri P
    Rev Neurol; 2022 Nov; 75(s05):S1-S89. PubMed ID: 36544369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    Psychopharmacology (Berl); 2020 Dec; 237(12):3665-3687. PubMed ID: 32851421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of neuroprotection against ischemic insult by stress-inducible phosphoprotein-1/prion protein complex.
    Beraldo FH; Ostapchenko VG; Xu JZ; Di Guglielmo GM; Fan J; Nicholls PJ; Caron MG; Prado VF; Prado MAM
    J Neurochem; 2018 Apr; 145(1):68-79. PubMed ID: 29265373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha7 nAChR Agonists for Cognitive Deficit and Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Double-blind Controlled Trials.
    Jin Y; Wang Q; Wang Y; Liu M; Sun A; Geng Z; Lin Y; Li X
    Shanghai Arch Psychiatry; 2017 Aug; 29(4):191-199. PubMed ID: 28955138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology.
    Geerts H; Roberts P; Spiros A
    Front Pharmacol; 2015; 6():198. PubMed ID: 26441655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.
    Stevens KE; Choo KS; Stitzel JA; Marks MJ; Adams CE
    Brain Res; 2014 Mar; 1552():26-33. PubMed ID: 24462939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
    Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
    Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats.
    Thomsen MS; El-Sayed M; Mikkelsen JD
    PLoS One; 2011; 6(11):e27014. PubMed ID: 22096516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
    Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
    Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
    Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
    J Psychopharmacol; 2023 Apr; 37(4):381-395. PubMed ID: 36927273
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.